SCHEMBL6010927

SCHEMBL6010927

CCOC(=O)c1cc(Cl)cc2nc(S)oc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.49
ESR2 Q92731 1/20 0.49
MAOB P27338 2/20 0.48
HSD17B10 Q99714 3/20 0.44
MAPK1 P28482 2/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAOA P21397 1/20 0.40
TARBP2 Q15633 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
TSHR P16473 3/20 0.38
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27577813 0.84 ESR1 (0.49) ESR1ESR2MAOBHSD17B10MAPK1
SCHEMBL16391312 0.80 MAOB (0.41) ESR1ESR2MAOBHSD17B10MAPK1
SCHEMBL12583780 0.77 HSD17B10 (0.46) ESR1ESR2MAOBHSD17B10KDM4E
SCHEMBL6010882 0.74 ESR1 (0.39) ESR1ESR2
SCHEMBL23315376 0.74 CA12 (0.42) ESR1ESR2HSD17B10ALDH1A1SMN1; SMN2
SCHEMBL21487412 0.74 MAOB (0.43) ESR1ESR2MAOBHSD17B10ALDH1A1
SCHEMBL16047286 0.72 ESR2 (0.47) ESR1ESR2HSD17B10MAPK1KDM4E
SCHEMBL5021458 0.72 NUDT1 (0.41) MAPK1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6010802 0.70 LMNA (0.43) HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL21487580 0.69 MAOB (0.43) ESR1ESR2MAOBHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020718-B1 NOVEL PDE4 INHIBITOR MEIJI SEIKA PHARMA CO LTD (JP) 2018-12-26 EP disclosed
US-9890142-B2 PDE4 inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-02-13 US disclosed
US-9850235-B2 2017-12-26 US disclosed
US-20160159783-A1 PDE4 Inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-06-09 US disclosed
EP-3020718-A1 NOVEL PDE4 INHIBITOR Meiji Seika Pharma Co., Ltd. (JP) 2016-05-18 EP disclosed
US-7045516-B1 Benzoxazole derivatives and drugs containing the same as the active ingredient KOICHI SHUDO (JP) 2006-05-16 US disclosed
EP-1134220-B1 BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT SHUDO KOICHI (JP) 2004-08-18 EP disclosed
CN-1333771-A Benzoxazole derivative and drug containing the same as active ingredient MEIJI SEIKA KAISHA (JP) 2002-01-30 CN disclosed
EP-1134220-A1 BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2001-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159783-A1 PDE4 Inhibitor PDE4A, PDE4B, PDE3B ESR1 3756/4885ESR2 3137/4885MAOB 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.